MedPath logo

LASIX TABLET 40 mg

Prescription Only
Drug type: Therapeutic
ATC code: C03CA01
Dosage form: TABLET
Route of administration: ORAL
Active ingredient: FUROSEMIDE; FUROSEMIDE

Indications

Oedema due to cardiac, hepatic, or renal disorders (in the presence of nephrotic syndrome, treatment of the basic disorder is the prime concern). Oedema due to burns. Mild to moderate hypertension.

Contraindications

Lasix must not be used in patients with:

  • renal failure accompanied by lack of urine formation (anuria) in patients not responding to furosemide
  • hepatic coma and precoma
  • severely reduced blood levels of potassium (hypokalaemia – see Adverse Reaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information), or of sodium (hyponatraemia)
  • decreased volume of blood in the body (hypovolaemia) – with or without reduced blood pressure (hypotension) – or dehydration
  • hypersensitivity to furosemide or any of the excipients (see “Composition” – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients allergic to sulphonamides (e.g. sulphonamide antibiotics or sulphonylureas) may show cross-sensitivity to furosemide.
  • lactation

Dosage

In general, the dose used must be the lowest which is sufficient to achieve the desired effect.

Unless otherwise prescribed, the following dosage guidelines apply:

In adults, treatment is usually started with 1/2–1–2 tablets daily; the maintenance dose is 1/2–1 tablet daily.

In infants and children, Lasix should in principle be administered orally. The dosage recommendation is 2 mg furosemide per kg body weight up to a daily maximum of 40 mg.

Parenteral administration (if necessary, continuous drip infusion) is indicated only in life-threatening conditions.

Registrant
SANOFI-AVENTIS SINGAPORE PTE. LTD.
Approval Date
1988-03-28
Approval Number
SIN00199P
Manufacturer
Opella Healthcare International SAS
Licence Holder
SANOFI-AVENTIS SINGAPORE PTE. LTD.